Tomotaka Shingaki

Tomotaka Shingaki

Auto-generated profile, based on publicly available information

Tomotaka Shingaki

RIKEN Center for Life Science Technologies, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2009 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
TSTomotaka Shingaki
Tomotaka Shingaki
IHIsmael J. Hidalgo
Ismael J. Hidalgo
Tomoyuki FurubayashiTomoyuki Furubayashi
Tomoyuki Furubayashi
HKHidemasa Katsumi
Hidemasa Katsumi
TSToshiyasu Sakane
Toshiyasu Sakane
SYShinji Yamashita
Shinji Yamashita

1 January 2011 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
TSTomotaka Shingaki
Tomotaka Shingaki
IHIsmael J. Hidalgo
Ismael J. Hidalgo
Tomoyuki FurubayashiTomoyuki Furubayashi
Tomoyuki Furubayashi
TSToshiyasu Sakane
Toshiyasu Sakane
HKHidemasa Katsumi
Hidemasa Katsumi
SYShinji Yamashita
Shinji Yamashita
The objective of this study was to evaluate in rats the potential utility of the nasal route to enhance central nervous system (CNS) delivery of drugs recognized by P-glycoprotein (P-gp). Well-known P-gp substrates verapamil and talinolol were perfused nasally or infused intravenously, and when plasma concentrations following intravenous infusion and nasal perfusion showed similar profiles. The concentration of verapamil in the brain after nasal perfusion was twice that after intravenous infusion. Although talinolol in the brain and the cerebrospinal fluid after i.v. infusion were below the detection limit, it was detected after nasal perfusion. When rats were treated with cyclosporin A, brain concentrations of verapamil after both administration modes were increased significantly, while those of talinolol were not significantly changed. Since the permeability of talinolol is low, talinolol in the brain which was transported directly from the nasal cavity has little chance of transport by P-gp localized in the apical membrane of cerebral microvessel endothelial cells. The potential for drug delivery utilizing the nose-CNS route was confirmed for P-gp substrates. The advantage of nasal delivery over i.v. delivery of talinolol to the brain was more significant than that of verapamil, suggesting that nasal administration is more useful strategy for the brain delivery of low-permeability P-gp substrates than the use of P-gp inhibitors.

1 February 2016 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
TSTomotaka Shingaki
Tomotaka Shingaki
YKYumiko Katayama
Yumiko Katayama
TNTakayoshi Nakaoka
Takayoshi Nakaoka
SISatsuki Irie
Satsuki Irie
KOKayo Onoe
Kayo Onoe
YWYasuyoshi Watanabe
Yasuyoshi Watanabe

1 January 1999 in Drug Delivery System
Verified
Journal Article
Open access
PDF file
TSTomotaka Shingaki
Tomotaka Shingaki
TSToshiyasu Sakane
Toshiyasu Sakane
SYShinji Yamashita
Shinji Yamashita
HSHitoshi Sezaki
Hitoshi Sezaki
YTYoshiharu Tokunaga
Yoshiharu Tokunaga
SSShobu Shibata
Shobu Shibata
総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。

11 February 2016 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
TSTomotaka Shingaki
Tomotaka Shingaki
YKYumiko Katayama
Yumiko Katayama
TNTakayoshi Nakaoka
Takayoshi Nakaoka
TTTadayuki Takashima
Tadayuki Takashima
KOKayo Onoe
Kayo Onoe
YWYasuyoshi Watanabe
Yasuyoshi Watanabe